Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Single-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASC43F, a Fixed-dose Combination (FDC) Oral Tablet Containing ASC41, a THR β Agonist and ASC42, an FXR Agonist in Healthy Subjects

Next Previous
Trial Profile

A Phase 1, Open-label, Single-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASC43F, a Fixed-dose Combination (FDC) Oral Tablet Containing ASC41, a THR β Agonist and ASC42, an FXR Agonist in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ASC-41/ASC-42 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions; First in man
  • Sponsors Gannex Pharma

Most Recent Events

  • 08 Nov 2022 Results of tolerability, safety profiles and PK parameters presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases
  • 06 Nov 2022 According to a Gannex Pharma media release, data from this study The Liver Meeting 2022 of the American Association for the Study of Liver Diseases (AASLD) as poster presentation.
  • 03 Jan 2022 Results published in Gannex Pharma Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top